{"text": ["3", "High-Yield", "Stocks", "for", "Dividend", "Investors"], "created_at": "2021-05-03 14:47:55"}
{"text": ["Novartis'", "Beovu", "Non-Inferior", "To", "Aflibercept", "In", "Phase", "3", "Diabetic", "Macular", "Edema", "Study"], "created_at": "2021-05-03 11:34:58"}
{"text": ["The", "Zacks", "Analyst", "Blog", "Highlights:", "Eli", "Lilly,", "Merck,", "GlaxoSmithKline,", "Novartis", "and", "Johnson", "&", "Johnson"], "created_at": "2021-05-03 10:42:10"}
{"text": ["Novartis", "biosimilar", "targets", "rivals'", "Eylea", "eye", "treatment"], "created_at": "2021-05-03 05:42:11"}
{"text": ["Sandoz", "confirms", "late-stage", "clinical", "development", "plans", "for", "proposed", "biosimilar", "aflibercept,", "a", "key", "ophthalmology", "medicine"], "created_at": "2021-05-03 05:15:00"}
